Misbranded epilepsy drug API lands FDA warning for Chinese ingredient maker

By Dan Stanton

- Last updated on GMT

Image: iStock/dk_photos
Image: iStock/dk_photos

Related tags Pharmaceutical drug

The US FDA has slammed China’s Lumis Global Pharmaceuticals for problems documenting and labelling active pharmaceutical ingredients.

The warning letter​ was sent on March 2 to Lumis following an inspection by the US Food and Drug Administration (FDA) at the firm’s active pharmaceutical ingredient (API) plant in Wuhan, Hubei last September.

The deviations from cGMP cited by the Agency included failures in the labelling of API made at the plant.

“You omitted the name and address of the original API manufacturers on the certificates of analysis (COA) you issued to your customers, and did not include copies of the original batch certificate​,” the FDA said.

“For multiple API, you generated COA by copying and pasting analytical results from the original API manufacturers, replacing the manufacturers’ information with your letterhead, then issuing these COA to your customers.”

The Agency also noted Lumis failed to record the time, date and the employee who conducted relabeling operations for distributed API.


One of the APIs packages at the facility is gabapentin, used to treat seizures and neuropathic pain. The label for the ingredient stated: “Manufactured under cGMP conditions by: Lumis Global Pharmaceuticals Co., Ltd,” ​which the FDA said was misleading.

“It indicates that the manufacturer of the API is Lumis Global Pharmaceuticals Co., Ltd. instead of (b)(4). Therefore, the gabapentin APIs is misbranded under section 502(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) in that the API labeling is misleading.”

“The label of Lumis’ API product is misbranded under section 502(b)(1) because it misidentifies Lumis, which is a distributor or packer, as the manufacturer. As evidenced by the certificates of analysis, (b)(4) is the manufacturer of the gabapentin API, not Lumis Global Pharmaceuticals Co. Ltd.”

And a further violation was that Lumis shipped drugs from a manufacturer on FDA Import Alert 66-66 – “APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122.”

According to the FDA, Lumis “shipped (b)(4) USP API manufactured by this firm to the United States in February 2015 and declared that [it was] the manufacturer on importation documents.”

Related news

Show more

Related products

show more

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

A Guide Through the API Drug Development Pipeline.

A Guide Through the API Drug Development Pipeline.

Content provided by Lonza Small Molecules | 04-Apr-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more